Outcome after imatinib therapy for patients in whom der(9) deletions was assessed versus those in whom it was not assessed
. | Assessment of der(9) deletions . | . | . | |
|---|---|---|---|---|
. | Investigated . | Not investigated . | P . | |
| Median age, y (range) | 51 (15-84) | 52 (16-81) | .65 | |
| Hasford, % | ||||
| Low | 53 | 50 | .38 | |
| Intermediate | 39 | 46 | ||
| High | 8 | 5 | ||
| Interferon failure, no. | 168 | 235 | ||
| Complete cytogenetic remission, % | 56 | 55 | .95 | |
| 3-y survival, % | 90 | 87 | .5 | |
| Previously untreated, no. | 152 | 61 | ||
| Complete cytogenetic remission, % | 82 | 77 | .45 | |
| 3-y survival, % | 95 | 95 | .99 | |
. | Assessment of der(9) deletions . | . | . | |
|---|---|---|---|---|
. | Investigated . | Not investigated . | P . | |
| Median age, y (range) | 51 (15-84) | 52 (16-81) | .65 | |
| Hasford, % | ||||
| Low | 53 | 50 | .38 | |
| Intermediate | 39 | 46 | ||
| High | 8 | 5 | ||
| Interferon failure, no. | 168 | 235 | ||
| Complete cytogenetic remission, % | 56 | 55 | .95 | |
| 3-y survival, % | 90 | 87 | .5 | |
| Previously untreated, no. | 152 | 61 | ||
| Complete cytogenetic remission, % | 82 | 77 | .45 | |
| 3-y survival, % | 95 | 95 | .99 | |